Asthma and Chronic Obstructive Pulmonary Disease (COPD) Drugs Market PORTLAND, OR, UNITED STATES, October 1, 2024 /EINPresswire.com/ -- ๐๐๐ญ ๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ ๐จ๐ ๐ญ๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ: https://www.alliedmarketresearch.com/request-sample/311
Allied Market Research has released an insightful new study on the Asthma and Chronic Obstructive Pulmonary Disease (COPD) Drugs Market, providing a comprehensive analysis of the market size, growth potential, and trends. The market was valued at $32,988.7 million in 2020 and is projected to reach $52,049.54 million by 2030, with a CAGR of 4.64% from 2021 to 2030.
Key Highlights:
Asthma is a chronic, non-communicable lung disorder characterized by airway inflammation, which leads to symptoms like wheezing, breathlessness, chest tightness, and coughing. It is largely reversible and often triggered by allergens and environmental irritants.
COPD is a progressive lung disease, including emphysema and chronic bronchitis, primarily caused by tobacco smoking. Unlike asthma, COPD is less reversible, leading to airflow limitations.
Asthma and COPD diagnosis typically involves physical examination, X-ray, sputum tests, and nitric oxide tests.
Treatment options include inhaled corticosteroids, beta agonists, and anticholinergic drugs. Advanced therapies, such as combination treatments, are proving effective in managing symptoms.
Market Drivers: Rising prevalence: Asthma affects approximately 262 million people globally, while 99 million adults in the U.S. have chronic bronchitis, according to health organizations.
New therapies: Product launches, such as AstraZenecaโs Trixeo Aerosphere, approved for COPD treatment in 2020, are driving market growth.
Technological advancements in respiratory therapy have significantly improved treatment outcomes, fostering market expansion.
Market Segmentation: By Disease: Divided into asthma and COPD categories, with the asthma segment leading in 2020. However, the COPD segment is expected to see substantial growth due to advancements in treatment.
By Medication Class: Key segments include combination drugs, inhaled corticosteroids (ICS), short-acting beta agonists (SABA), long-acting beta agonists (LABA), leukotriene antagonists, and anticholinergics. Combination drugs dominated in 2020, but the ICS segment is projected to grow rapidly.
Regional Insights: North America: This region led the market in 2020, driven by factors like the high prevalence of asthma, advanced infrastructure, and a high rate of smoking.
Asia-Pacific: Expected to experience the highest growth rate (CAGR of 5.81%) from 2021 to 2030 due to an increasing number of hospitals and a growing population.
Challenges: High treatment costs are a major barrier to the growth of the asthma and COPD drugs market, particularly in developing countries.
๐๐ง๐ช๐ฎ๐ข๐ซ๐ ๐๐๐๐จ๐ซ๐ ๐๐ฎ๐ฒ๐ข๐ง๐ : https://www.alliedmarketresearch.com/purchase-enquiry/311
David CorreaAllied Market Research+1 800-792-5285email us hereVisit us on social media:FacebookX
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
You just read:
News Provided By
October 01, 2024, 06:18 GMT
EIN Presswire's priority is author transparency. We do our best to weed out false and misleading content. The content above is the sole responsibility of the author who makes it available. If you have any complaints, kindly contact the author above. Article originally published on www.einpresswire.com as $52,049.54+ million Asthma and COPD Drugs Market is poised for significant growth over the next decade
